950 related articles for article (PubMed ID: 12420225)
1. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
2. Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency.
Periyasamy S; Ammanamanchi S; Tillekeratne MP; Brattain MG
Oncogene; 2000 Sep; 19(40):4660-7. PubMed ID: 11030155
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
Adnane J; Bizouarn FA; Chen Z; Ohkanda J; Hamilton AD; Munoz-Antonia T; Sebti SM
Oncogene; 2000 Nov; 19(48):5525-33. PubMed ID: 11114730
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
5. Reversion of transcriptional repression of Sp1 by 5 aza-2' deoxycytidine restores TGF-beta type II receptor expression in the pancreatic cancer cell line MIA PaCa-2.
Venkatasubbarao K; Ammanamanchi S; Brattain MG; Mimari D; Freeman JW
Cancer Res; 2001 Aug; 61(16):6239-47. PubMed ID: 11507078
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma.
Venkatasubbarao K; Ahmed MM; Mohiuddin M; Swiderski C; Lee E; Gower WR; Salhab KF; McGrath P; Strodel W; Freeman JW
Anticancer Res; 2000; 20(1A):43-51. PubMed ID: 10769633
[TBL] [Abstract][Full Text] [Related]
7. Rap1 reverses transcriptional repression of TGF-beta type II receptor by a mechanism involving AP-1 in the human pancreatic cancer cell line, UK Pan-1.
Fralix KD; Zhao S; Venkatasubbarao K; Freeman JW
J Cell Physiol; 2003 Jan; 194(1):88-99. PubMed ID: 12447993
[TBL] [Abstract][Full Text] [Related]
8. Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2.
Ahmed MM; Alcock RA; Chendil D; Dey S; Das A; Venkatasubbarao K; Mohiuddin M; Sun L; Strodel WE; Freeman JW
J Biol Chem; 2002 Jan; 277(3):2234-46. PubMed ID: 11694525
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
10. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
Guo Y; Kyprianou N
Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.
Shi Y; Wu J; Mick R; Cerniglia GJ; Cohen-Jonathan E; Rhim JS; Koch CJ; Bernhard EJ
Prostate; 2005 Jan; 62(1):69-82. PubMed ID: 15389805
[TBL] [Abstract][Full Text] [Related]
13. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.
Mohiuddin M; Chendil D; Dey S; Alcock RA; Regine W; Mohiuddin M; Ahmed MM
Anticancer Res; 2002; 22(2A):825-30. PubMed ID: 12014658
[TBL] [Abstract][Full Text] [Related]
14. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
Nørgaard P; Law B; Joseph H; Page DL; Shyr Y; Mays D; Pietenpol JA; Kohl NE; Oliff A; Coffey RJ; Poulsen HS; Moses HL
Clin Cancer Res; 1999 Jan; 5(1):35-42. PubMed ID: 9918200
[TBL] [Abstract][Full Text] [Related]
15. Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells.
Grau AM; Zhang L; Wang W; Ruan S; Evans DB; Abbruzzese JL; Zhang W; Chiao PJ
Cancer Res; 1997 Sep; 57(18):3929-34. PubMed ID: 9307274
[TBL] [Abstract][Full Text] [Related]
16. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Guo Y; Kyprianou N
Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
[TBL] [Abstract][Full Text] [Related]
17. Increased tumorigenicity in the human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF-beta type RII receptor.
Freeman JW; Mattingly CA; Strodel WE
J Cell Physiol; 1995 Oct; 165(1):155-63. PubMed ID: 7559796
[TBL] [Abstract][Full Text] [Related]
18. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells.
Matsuyama S; Iwadate M; Kondo M; Saitoh M; Hanyu A; Shimizu K; Aburatani H; Mishima HK; Imamura T; Miyazono K; Miyazawa K
Cancer Res; 2003 Nov; 63(22):7791-8. PubMed ID: 14633705
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
20. Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta.
Ijichi H; Otsuka M; Tateishi K; Ikenoue T; Kawakami T; Kanai F; Arakawa Y; Seki N; Shimizu K; Miyazono K; Kawabe T; Omata M
Oncogene; 2004 Feb; 23(5):1043-51. PubMed ID: 14762439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
